Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts
Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang
Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors
NevGold Appoints Dale Found as CFO, Current CFO Bob McKnight Transitions to VP Engineering Studies To Support Next Project Development Phase
Skyharbour Files Independent NI 43-101 Technical Reports on its Co-Flagship Moore and Russell Lake Uranium Projects, Saskatchewan
Red Metal Resources Reports First Ore Delivery from Farellon Ahead of Schedule, Launching Non-Dilutive Royalty Revenue
